Acorda Therapeutics Inc (NASDAQ:ACOR) has been assigned a consensus recommendation of “Hold” from the eighteen analysts that are covering the stock, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, eleven have assigned a hold recommendation, three have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price target among analysts that have covered the stock in the last year is $23.05.
Several research analysts have recently issued reports on ACOR shares. Zacks Investment Research cut Acorda Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Monday, October 30th. Cantor Fitzgerald reaffirmed a “hold” rating and set a $18.00 price objective on shares of Acorda Therapeutics in a research report on Tuesday, October 31st. JPMorgan Chase & Co. set a $24.00 price objective on Acorda Therapeutics and gave the stock a “hold” rating in a research report on Tuesday, October 31st. Jefferies Group upped their price objective on Acorda Therapeutics from $22.00 to $25.00 and gave the stock a “hold” rating in a research report on Wednesday, November 1st. Finally, HC Wainwright started coverage on Acorda Therapeutics in a research report on Wednesday, November 8th. They set a “buy” rating and a $35.00 price objective for the company.
Acorda Therapeutics (ACOR) traded up $0.70 during trading hours on Wednesday, hitting $25.80. The stock had a trading volume of 645,700 shares, compared to its average volume of 796,164. Acorda Therapeutics has a twelve month low of $13.60 and a twelve month high of $33.00. The company has a quick ratio of 2.81, a current ratio of 3.07 and a debt-to-equity ratio of 0.64.
Acorda Therapeutics (NASDAQ:ACOR) last released its quarterly earnings data on Thursday, February 15th. The biopharmaceutical company reported $0.61 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.88 by ($0.27). The business had revenue of $188.40 million for the quarter, compared to analyst estimates of $171.70 million. Acorda Therapeutics had a negative return on equity of 4.88% and a negative net margin of 37.97%. The company’s revenue was up 34.0% compared to the same quarter last year. During the same period in the prior year, the company posted $0.05 earnings per share. research analysts forecast that Acorda Therapeutics will post -0.41 earnings per share for the current year.
In other news, insider David Lawrence sold 31,000 shares of the business’s stock in a transaction dated Friday, January 19th. The stock was sold at an average price of $27.58, for a total value of $854,980.00. Following the completion of the sale, the insider now directly owns 5,275 shares of the company’s stock, valued at approximately $145,484.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Burkhard Blank sold 11,050 shares of the business’s stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $20.53, for a total value of $226,856.50. Following the completion of the sale, the insider now directly owns 33,150 shares of the company’s stock, valued at $680,569.50. The disclosure for this sale can be found here. 7.90% of the stock is currently owned by insiders.
Several institutional investors have recently bought and sold shares of ACOR. Vanguard Group Inc. raised its stake in Acorda Therapeutics by 4.1% during the 2nd quarter. Vanguard Group Inc. now owns 4,308,160 shares of the biopharmaceutical company’s stock valued at $84,871,000 after acquiring an additional 168,571 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in Acorda Therapeutics by 11.9% during the 3rd quarter. Dimensional Fund Advisors LP now owns 2,655,959 shares of the biopharmaceutical company’s stock valued at $62,813,000 after acquiring an additional 283,091 shares during the last quarter. State Street Corp raised its stake in Acorda Therapeutics by 52.4% during the 2nd quarter. State Street Corp now owns 2,476,033 shares of the biopharmaceutical company’s stock valued at $48,783,000 after acquiring an additional 851,290 shares during the last quarter. Northern Trust Corp raised its stake in Acorda Therapeutics by 65.2% during the 2nd quarter. Northern Trust Corp now owns 897,974 shares of the biopharmaceutical company’s stock valued at $17,690,000 after acquiring an additional 354,304 shares during the last quarter. Finally, Macquarie Group Ltd. raised its stake in Acorda Therapeutics by 13.7% during the 3rd quarter. Macquarie Group Ltd. now owns 683,761 shares of the biopharmaceutical company’s stock valued at $16,171,000 after acquiring an additional 82,642 shares during the last quarter.
TRADEMARK VIOLATION NOTICE: “Analysts Set Acorda Therapeutics Inc (ACOR) Price Target at $21.69” was published by The Lincolnian Online and is the property of of The Lincolnian Online. If you are viewing this article on another site, it was illegally copied and reposted in violation of international trademark and copyright law. The legal version of this article can be accessed at https://www.thelincolnianonline.com/2018/02/19/analysts-set-acorda-therapeutics-inc-acor-price-target-at-21-69.html.
About Acorda Therapeutics
Acorda Therapeutics, Inc is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS).
Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.